Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – Time to Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s share price gapped up prior to trading on Monday . The stock had previously closed at $14.56, but opened at $15.4168. Astellas Pharma shares last traded at $14.85, with a volume of 11,098 shares traded.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Astellas Pharma Stock Up 1.6%

The business’s 50 day moving average is $14.19 and its 200 day moving average is $14.57. The company has a market capitalization of $26.76 billion, a price-to-earnings ratio of 11.26 and a beta of 0.08. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.93 and a current ratio of 1.20.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops and commercializes prescription medicines for serious and unmet medical needs. Its research and commercial activities focus on areas including oncology, urology, immunology, neuromuscular diseases, ophthalmology and other specialty conditions.

The company’s portfolio includes treatments such as XTANDI for certain prostate cancers, XOSPATA for acute myeloid leukemia, MYRBETRIQ for overactive bladder and VEOZAH for menopausal hot flashes.